Therefore, the compounds might be working at the point of attachment blocking interaction of Chlamydia with the eukaryotic cell surface receptor but pre-treatment of the host cell is not as effective as when the compounds are present together with chlamydial EBs at the time of infection. This evidence concerns the gene CD177 and infection.